Assessing the Safety and Activity of Cabozantinib Combined with Lanreotide in Gastroenteropancreatic and Thoracic Neuroendocrine Tumors: Rationale and Protocol of the Phase II LOLA Trial.
BMC Cancer（2023）
关键词
Neuroendocrine tumors,Lanreotide,Cabozantinib,Somatostatin analogs,Tyrosine kinase inhibitors,Clinical trial
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要